162 related articles for article (PubMed ID: 35794897)
1. Humoral Immune Response to Inactivated COVID-19 Vaccination at the 3rd Month among People Living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
Res Sq; 2022 Jun; ():. PubMed ID: 35794897
[No Abstract] [Full Text] [Related]
2. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
3. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV.
Zou S; Guo W; Wu S; Ming F; Tan Y; Wu M; Tang W; Liang K
Front Immunol; 2022; 13():988304. PubMed ID: 36325346
[TBL] [Abstract][Full Text] [Related]
4. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.
Zou S; Wu M; Ming F; Wu S; Guo W; Marley G; Xing Z; Zhang Z; Zeng M; Sun C; Zhang J; Tang W; Liang K
AIDS Res Ther; 2022 Jul; 19(1):33. PubMed ID: 35791004
[TBL] [Abstract][Full Text] [Related]
5. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
6. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to two doses of COVID-19 mRNA-based vaccines in people living with HIV: A systematic review and meta-analysis.
Farhadian N; Sharifi S; Taghadosi M; Farhadian M; Vaziri S
Rev Med Virol; 2023 Jul; 33(4):e2451. PubMed ID: 37072909
[TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of CD4
Zhang W; Liu S; Miao L; Fu A; Bao J; Zheng L; Li E; Yu J; Wang Y
Infect Drug Resist; 2023; 16():2695-2707. PubMed ID: 37168513
[TBL] [Abstract][Full Text] [Related]
11. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
[TBL] [Abstract][Full Text] [Related]
15. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
Wang Y; Li J; Zhang W; Liu S; Miao L; Li Z; Fu A; Bao J; Huang L; Zheng L; Li E; Zhang Y; Yu J
Front Immunol; 2023; 14():1152695. PubMed ID: 36936952
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
Cai S; Liao G; Yu T; Gao Q; Zou L; Zhang H; Xu X; Chen J; Lu A; Wu Y; Li B; Peng J
J Med Virol; 2022 Sep; 94(9):4224-4233. PubMed ID: 35585023
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
Feng Y; Zhang Y; He Z; Huang H; Tian X; Wang G; Chen D; Ren Y; Jia L; Wang W; Wu J; Shao L; Zhang W; Tang H; Wan Y
EClinicalMedicine; 2022 Jan; 43():101226. PubMed ID: 34901799
[TBL] [Abstract][Full Text] [Related]
18. High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
Pourcher V; Belin L; Soulie C; Rosenzwajg M; Marot S; Lacombe K; Valin N; Pialoux G; Calin R; Palacios C; Malet I; Zafilaza K; Tubiana R; Valantin MA; Klatzmann D; Calvez V; Simon-Tillaux N; Marcelin AG
AIDS; 2022 Sep; 36(11):1545-1552. PubMed ID: 35730380
[TBL] [Abstract][Full Text] [Related]
19. The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus.
Matsumoto Y; Murata M; Ohta A; Yamasaki S; Ikezaki H; Toyoda K; Shimono N
J Infect Chemother; 2024 May; 30(5):417-422. PubMed ID: 37977325
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China.
Han X; Yu X; Han Y; Fang Q; Shen C; Liu H; Wang P; Wang Y; Li X
Infect Drug Resist; 2022; 15():2091-2100. PubMed ID: 35480056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
